Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility
about
Purinergic signaling in schistosomal infectionGenetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoniTranscriptional responses of in vivo praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKIIPraziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infectionsInhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to PraziquantelThe Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant PhenotypeModulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel.Use of fluorescent probes as a useful tool to identify resistant Schistosoma mansoni isolates to praziquantel.Polymorphism in ABC transporter genes of Dirofilaria immitis.Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam.Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infectionSchistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantelEpigenetic control of gene function in schistosomes: a source of therapeutic targets?Pharmacology and potential physiological significance of schistosome multidrug resistance transportersIntracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro.ABC multidrug transporters in schistosomes and other parasitic flatwormsNew approaches for understanding mechanisms of drug resistance in schistosomesP-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance.The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis.ABC transporters involved in drug resistance in human parasites.Ca²⁺ channels and praziquantel: a view from the free worldDrug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race.Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil.Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni.Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs.
P2860
Q28073072-DD60A90F-09BA-4C5A-A4F2-9A7C432097DEQ28478288-3E4D3979-10A1-4023-A5EF-448EE8FD932CQ28489110-00862156-C9B6-406D-BD88-35F50423614DQ28537753-9D070E72-29D7-4AE2-84A6-A58B937CEAF5Q28543846-C2141E75-0DDB-435B-97BB-D097F99B124AQ28550120-BDFBFE3E-2318-4BAF-8297-319B0021580FQ33552868-626CAB41-094A-46CF-8272-7A505711B689Q33609296-3F080E09-7F14-4E0D-98B7-0844E693405AQ33648348-98525446-B5FD-461F-B779-4A599BB4F531Q33825627-A1E1480D-EF1B-4A05-BAC9-D89E9C378B6FQ33884547-3F42F981-1073-4CBC-A2FD-6E2FED70F137Q33960332-9966143A-FB64-49CE-9A56-4B2F88AAAB8DQ34159188-59324A5B-465C-4B67-8F03-03779B74D919Q35159499-41EA86D7-8603-4FD4-AD83-4AD56926C398Q36103626-E068960E-B237-4148-B962-0758ED3F73AEQ36362462-8BC17E61-13C9-4108-8691-38569F2D8A30Q36442593-75FB2120-42E7-4A38-B9B5-D211374BE993Q37053762-ED14DADC-12A5-409B-A77D-4D75AEFB748DQ37177725-2BF38A5B-CED0-48BC-87B9-E1F73D9263E3Q37390601-EAC8ABB8-4A15-40C4-AB12-AA5953D974E8Q37726847-DAA8F3C4-33A8-4BC6-A386-7FC725C3A88FQ37941754-787EE17F-EF0F-4DE1-A695-15D0C09F10C0Q38067995-B9CE0FF7-9D17-4482-A6E3-20500926B40DQ38118386-A8B06C45-9FEF-475E-B65C-DD12AC1CBA24Q42485937-EE06570D-52CB-4E28-83B5-77CFA449C405Q42493268-C030E2C0-7F04-459C-9603-58C0EA43F9A9Q43788758-59DAC18F-9473-4653-A5D5-3747D6067FB8Q48237579-845CEDE1-E89C-4939-A9C9-528D80071B16Q49197054-8B404357-00A6-4420-B962-B8B98B730EA1
P2860
Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Schistosoma mansoni P-glycopro ...... ed praziquantel susceptibility
@en
Schistosoma mansoni P-glycopro ...... d praziquantel susceptibility.
@nl
type
label
Schistosoma mansoni P-glycopro ...... ed praziquantel susceptibility
@en
Schistosoma mansoni P-glycopro ...... d praziquantel susceptibility.
@nl
prefLabel
Schistosoma mansoni P-glycopro ...... ed praziquantel susceptibility
@en
Schistosoma mansoni P-glycopro ...... d praziquantel susceptibility.
@nl
P2093
P2860
P1476
Schistosoma mansoni P-glycopro ...... ed praziquantel susceptibility
@en
P2093
Ravi S Kasinathan
Robert M Greenberg
Shanta M Messerli
Stefani Spranger
William Morgan
P2860
P356
10.1016/J.MOLBIOPARA.2009.04.007
P577
2009-05-03T00:00:00Z